Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 294 | 2024 | 5704 | 16.800 |
Why?
|
Proto-Oncogene Proteins B-raf | 165 | 2024 | 2052 | 13.870 |
Why?
|
Protein Kinase Inhibitors | 118 | 2024 | 5662 | 5.920 |
Why?
|
Pyrimidinones | 41 | 2024 | 384 | 5.800 |
Why?
|
Skin Neoplasms | 109 | 2024 | 5815 | 5.210 |
Why?
|
Antineoplastic Agents | 122 | 2024 | 13616 | 4.720 |
Why?
|
Pyridones | 40 | 2024 | 807 | 4.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 85 | 2024 | 11729 | 4.270 |
Why?
|
Oximes | 35 | 2022 | 303 | 4.190 |
Why?
|
Indoles | 57 | 2024 | 1833 | 3.970 |
Why?
|
Sulfonamides | 59 | 2024 | 1973 | 3.870 |
Why?
|
Imidazoles | 42 | 2022 | 1179 | 3.480 |
Why?
|
Drug Resistance, Neoplasm | 79 | 2024 | 5292 | 3.370 |
Why?
|
Benzenesulfonates | 21 | 2013 | 166 | 2.940 |
Why?
|
Molecular Targeted Therapy | 46 | 2024 | 2805 | 2.910 |
Why?
|
Mutation | 113 | 2024 | 30025 | 2.820 |
Why?
|
Benzimidazoles | 17 | 2024 | 855 | 2.760 |
Why?
|
Neoplasms | 66 | 2024 | 22083 | 2.680 |
Why?
|
Carbamates | 7 | 2024 | 191 | 2.190 |
Why?
|
MAP Kinase Signaling System | 30 | 2018 | 1485 | 2.180 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 24 | 2023 | 641 | 2.140 |
Why?
|
Phenylurea Compounds | 33 | 2019 | 528 | 2.070 |
Why?
|
Pyridines | 30 | 2023 | 2868 | 2.020 |
Why?
|
Immunotherapy | 38 | 2023 | 4649 | 1.900 |
Why?
|
Carcinoma, Renal Cell | 28 | 2021 | 3159 | 1.840 |
Why?
|
Mitogen-Activated Protein Kinases | 21 | 2022 | 1246 | 1.730 |
Why?
|
Niacinamide | 31 | 2017 | 413 | 1.670 |
Why?
|
Kidney Neoplasms | 27 | 2021 | 4241 | 1.630 |
Why?
|
Quinoxalines | 2 | 2024 | 296 | 1.580 |
Why?
|
GTP Phosphohydrolases | 10 | 2024 | 516 | 1.400 |
Why?
|
MAP Kinase Kinase Kinases | 11 | 2020 | 255 | 1.340 |
Why?
|
Neoplasm Metastasis | 44 | 2024 | 4903 | 1.300 |
Why?
|
MAP Kinase Kinase 1 | 11 | 2020 | 331 | 1.290 |
Why?
|
Pyrazoles | 4 | 2024 | 2007 | 1.290 |
Why?
|
National Cancer Institute (U.S.) | 8 | 2024 | 295 | 1.270 |
Why?
|
Clinical Trials as Topic | 33 | 2024 | 7996 | 1.200 |
Why?
|
Humans | 436 | 2024 | 760437 | 1.180 |
Why?
|
Disease-Free Survival | 39 | 2021 | 6813 | 1.040 |
Why?
|
Cell Line, Tumor | 89 | 2024 | 16945 | 1.030 |
Why?
|
Receptor, erbB-2 | 6 | 2024 | 2553 | 1.010 |
Why?
|
Microphthalmia-Associated Transcription Factor | 8 | 2019 | 259 | 0.990 |
Why?
|
Piperazines | 13 | 2023 | 2519 | 0.980 |
Why?
|
Signal Transduction | 58 | 2020 | 23397 | 0.940 |
Why?
|
MAP Kinase Kinase 2 | 5 | 2020 | 92 | 0.910 |
Why?
|
Xenograft Model Antitumor Assays | 32 | 2024 | 3590 | 0.860 |
Why?
|
Immunologic Factors | 6 | 2020 | 1588 | 0.840 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 8 | 2019 | 664 | 0.840 |
Why?
|
Maximum Tolerated Dose | 12 | 2019 | 882 | 0.830 |
Why?
|
Middle Aged | 142 | 2024 | 220382 | 0.820 |
Why?
|
Quinazolines | 8 | 2022 | 1371 | 0.820 |
Why?
|
Pyrimidines | 10 | 2024 | 3024 | 0.810 |
Why?
|
Acrylamides | 1 | 2024 | 259 | 0.800 |
Why?
|
Aniline Compounds | 3 | 2024 | 1069 | 0.800 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2024 | 3631 | 0.790 |
Why?
|
Aged, 80 and over | 67 | 2024 | 58859 | 0.780 |
Why?
|
Periodicals as Topic | 8 | 2022 | 1463 | 0.760 |
Why?
|
Antibodies, Monoclonal | 25 | 2021 | 9176 | 0.760 |
Why?
|
Aged | 118 | 2024 | 168840 | 0.750 |
Why?
|
Drug Discovery | 4 | 2017 | 1054 | 0.750 |
Why?
|
Ameloblastoma | 1 | 2021 | 42 | 0.730 |
Why?
|
Codon | 4 | 2021 | 602 | 0.730 |
Why?
|
Neutropenia | 5 | 2023 | 884 | 0.720 |
Why?
|
Jaw Neoplasms | 1 | 2021 | 70 | 0.720 |
Why?
|
Breast Neoplasms | 8 | 2024 | 20985 | 0.710 |
Why?
|
Female | 181 | 2024 | 391875 | 0.710 |
Why?
|
Drug Eruptions | 4 | 2018 | 335 | 0.700 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2024 | 339 | 0.690 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 11 | 2016 | 614 | 0.680 |
Why?
|
Pyrroles | 8 | 2021 | 1126 | 0.680 |
Why?
|
Apoptosis | 35 | 2021 | 9468 | 0.680 |
Why?
|
Phosphatidylinositol 3-Kinases | 11 | 2022 | 2860 | 0.680 |
Why?
|
Gene Expression Regulation, Neoplastic | 35 | 2024 | 8519 | 0.670 |
Why?
|
Genes, ras | 10 | 2019 | 653 | 0.670 |
Why?
|
Benzamides | 7 | 2020 | 1370 | 0.660 |
Why?
|
Uveal Neoplasms | 6 | 2019 | 341 | 0.650 |
Why?
|
Adult | 111 | 2024 | 220781 | 0.640 |
Why?
|
Membrane Proteins | 12 | 2021 | 7849 | 0.630 |
Why?
|
Male | 160 | 2024 | 360035 | 0.620 |
Why?
|
Neoplasm Staging | 36 | 2021 | 11096 | 0.610 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2022 | 2911 | 0.610 |
Why?
|
Deoxycytidine | 6 | 2020 | 874 | 0.610 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 800 | 0.610 |
Why?
|
Neurofibromatosis 1 | 1 | 2023 | 560 | 0.600 |
Why?
|
Carboplatin | 8 | 2015 | 793 | 0.600 |
Why?
|
Paclitaxel | 12 | 2020 | 1732 | 0.600 |
Why?
|
Brain Neoplasms | 15 | 2024 | 9003 | 0.590 |
Why?
|
Neoplasm Proteins | 12 | 2018 | 3610 | 0.580 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 245 | 0.570 |
Why?
|
Cyclin-Dependent Kinases | 4 | 2014 | 653 | 0.560 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2023 | 4575 | 0.560 |
Why?
|
Proto-Oncogene Proteins c-kit | 11 | 2021 | 727 | 0.540 |
Why?
|
Animals | 108 | 2024 | 168253 | 0.540 |
Why?
|
Triazoles | 3 | 2018 | 903 | 0.530 |
Why?
|
Indazoles | 1 | 2018 | 302 | 0.530 |
Why?
|
Pyrrolidines | 1 | 2018 | 338 | 0.520 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2024 | 1605 | 0.520 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2024 | 256 | 0.520 |
Why?
|
Congresses as Topic | 4 | 2020 | 802 | 0.500 |
Why?
|
Cyclin-Dependent Kinase 4 | 6 | 2019 | 556 | 0.500 |
Why?
|
Dacarbazine | 9 | 2020 | 559 | 0.500 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2022 | 1355 | 0.500 |
Why?
|
Disease Progression | 30 | 2022 | 13484 | 0.490 |
Why?
|
Treatment Outcome | 58 | 2024 | 64591 | 0.480 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2021 | 716 | 0.470 |
Why?
|
Orphan Nuclear Receptors | 1 | 2014 | 63 | 0.460 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2019 | 3486 | 0.460 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2024 | 105 | 0.450 |
Why?
|
Melanocytes | 7 | 2021 | 509 | 0.450 |
Why?
|
Tumor Microenvironment | 13 | 2023 | 3874 | 0.450 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2015 | 357 | 0.450 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2015 | 611 | 0.440 |
Why?
|
Receptors, Fibroblast Growth Factor | 2 | 2024 | 191 | 0.440 |
Why?
|
Interferon-gamma | 4 | 2023 | 3157 | 0.430 |
Why?
|
Prognosis | 41 | 2021 | 29551 | 0.430 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2020 | 628 | 0.430 |
Why?
|
Kaplan-Meier Estimate | 21 | 2019 | 6471 | 0.430 |
Why?
|
Mice | 74 | 2024 | 81402 | 0.430 |
Why?
|
Young Adult | 37 | 2024 | 59068 | 0.420 |
Why?
|
Colorectal Neoplasms | 5 | 2021 | 6894 | 0.410 |
Why?
|
Drug Delivery Systems | 8 | 2017 | 2224 | 0.410 |
Why?
|
src-Family Kinases | 1 | 2015 | 535 | 0.400 |
Why?
|
Survival Rate | 22 | 2021 | 12698 | 0.400 |
Why?
|
Alleles | 3 | 2022 | 6908 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-raf | 7 | 2017 | 203 | 0.380 |
Why?
|
United States Food and Drug Administration | 6 | 2021 | 1663 | 0.380 |
Why?
|
Nausea | 6 | 2022 | 679 | 0.370 |
Why?
|
Research Design | 8 | 2024 | 6168 | 0.370 |
Why?
|
Chemotherapy, Adjuvant | 14 | 2021 | 3512 | 0.370 |
Why?
|
Lung Neoplasms | 6 | 2024 | 13312 | 0.370 |
Why?
|
Angiogenesis Inhibitors | 9 | 2013 | 2047 | 0.360 |
Why?
|
Mice, Nude | 18 | 2024 | 3603 | 0.360 |
Why?
|
Proto-Oncogene Proteins c-akt | 11 | 2021 | 2453 | 0.360 |
Why?
|
Lymphoma | 1 | 2020 | 1901 | 0.360 |
Why?
|
Azetidines | 6 | 2021 | 140 | 0.350 |
Why?
|
Gene Amplification | 7 | 2019 | 1086 | 0.350 |
Why?
|
Cell Proliferation | 23 | 2024 | 10425 | 0.340 |
Why?
|
United States | 25 | 2024 | 72202 | 0.340 |
Why?
|
Receptors, Nerve Growth Factor | 2 | 2021 | 198 | 0.340 |
Why?
|
Phosphoproteins | 3 | 2015 | 2444 | 0.340 |
Why?
|
Interferons | 3 | 2022 | 704 | 0.340 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 897 | 0.330 |
Why?
|
Fever | 5 | 2021 | 1618 | 0.330 |
Why?
|
Drug Therapy, Combination | 4 | 2015 | 6297 | 0.330 |
Why?
|
Drug Design | 3 | 2013 | 1050 | 0.330 |
Why?
|
Pyrazines | 1 | 2015 | 1199 | 0.320 |
Why?
|
Administration, Oral | 12 | 2019 | 4010 | 0.320 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5296 | 0.320 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2022 | 4020 | 0.320 |
Why?
|
Drug Administration Schedule | 15 | 2019 | 4849 | 0.310 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2011 | 412 | 0.310 |
Why?
|
ras Proteins | 6 | 2016 | 1052 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 2017 | 988 | 0.310 |
Why?
|
Cyclin D1 | 4 | 2023 | 451 | 0.300 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1741 | 0.300 |
Why?
|
Enzyme Inhibitors | 8 | 2024 | 3710 | 0.300 |
Why?
|
Isoenzymes | 2 | 2011 | 1688 | 0.300 |
Why?
|
Dose-Response Relationship, Drug | 16 | 2018 | 10759 | 0.300 |
Why?
|
Combined Modality Therapy | 10 | 2023 | 8522 | 0.290 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2015 | 2895 | 0.290 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 3 | 2018 | 472 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 7 | 2019 | 1404 | 0.280 |
Why?
|
Diarrhea | 4 | 2022 | 1319 | 0.280 |
Why?
|
Genomics | 5 | 2024 | 5806 | 0.280 |
Why?
|
Piperidines | 8 | 2021 | 1656 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2022 | 10180 | 0.270 |
Why?
|
TOR Serine-Threonine Kinases | 8 | 2017 | 2058 | 0.270 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2022 | 857 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2021 | 9267 | 0.260 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2018 | 476 | 0.260 |
Why?
|
Nephrectomy | 3 | 2021 | 934 | 0.260 |
Why?
|
Time Factors | 23 | 2022 | 39947 | 0.260 |
Why?
|
Tumor Cells, Cultured | 13 | 2021 | 6128 | 0.260 |
Why?
|
Double-Blind Method | 13 | 2021 | 12320 | 0.260 |
Why?
|
Survival Analysis | 16 | 2024 | 10075 | 0.250 |
Why?
|
Decision Support Techniques | 1 | 2015 | 1998 | 0.250 |
Why?
|
Oncogene Proteins | 1 | 2009 | 718 | 0.240 |
Why?
|
raf Kinases | 3 | 2015 | 118 | 0.240 |
Why?
|
Neovascularization, Pathologic | 4 | 2017 | 2642 | 0.240 |
Why?
|
Tamoxifen | 3 | 2015 | 964 | 0.240 |
Why?
|
Receptor, EphA2 | 2 | 2014 | 41 | 0.240 |
Why?
|
Mice, SCID | 10 | 2021 | 2625 | 0.240 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2018 | 345 | 0.240 |
Why?
|
Receptors, Estrogen | 2 | 2023 | 2204 | 0.230 |
Why?
|
Quality of Life | 4 | 2021 | 13338 | 0.230 |
Why?
|
Ploidies | 1 | 2024 | 284 | 0.230 |
Why?
|
Biopsy | 6 | 2020 | 6765 | 0.230 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2023 | 147 | 0.230 |
Why?
|
Neoplasms, Second Primary | 3 | 2022 | 1051 | 0.230 |
Why?
|
Area Under Curve | 6 | 2012 | 1633 | 0.230 |
Why?
|
Melanoma, Experimental | 4 | 2015 | 559 | 0.220 |
Why?
|
Medical Oncology | 6 | 2023 | 2318 | 0.220 |
Why?
|
Cell Cycle | 8 | 2019 | 2929 | 0.220 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2014 | 2870 | 0.220 |
Why?
|
Inhibitor of Apoptosis Proteins | 3 | 2023 | 196 | 0.220 |
Why?
|
DNA Mutational Analysis | 9 | 2016 | 4108 | 0.220 |
Why?
|
Membrane Glycoproteins | 4 | 2019 | 3701 | 0.210 |
Why?
|
Aminopyridines | 2 | 2017 | 570 | 0.210 |
Why?
|
Patient Selection | 5 | 2019 | 4240 | 0.210 |
Why?
|
PTEN Phosphohydrolase | 4 | 2016 | 1114 | 0.210 |
Why?
|
Antibodies, Catalytic | 1 | 2022 | 1 | 0.210 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2015 | 326 | 0.210 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2018 | 1624 | 0.210 |
Why?
|
Thionucleosides | 2 | 2021 | 13 | 0.210 |
Why?
|
Neural Stem Cells | 2 | 2021 | 888 | 0.210 |
Why?
|
Organoplatinum Compounds | 1 | 2004 | 407 | 0.210 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2023 | 102 | 0.200 |
Why?
|
bcl-X Protein | 1 | 2024 | 410 | 0.200 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2017 | 1089 | 0.200 |
Why?
|
Tumor Escape | 4 | 2020 | 370 | 0.200 |
Why?
|
Piperidones | 1 | 2022 | 37 | 0.200 |
Why?
|
Oxazepines | 1 | 2022 | 22 | 0.200 |
Why?
|
Deoxyguanosine | 2 | 2021 | 93 | 0.200 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 58 | 0.190 |
Why?
|
Interferon-alpha | 4 | 2016 | 920 | 0.190 |
Why?
|
Biomedical Research | 6 | 2021 | 3421 | 0.190 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2017 | 1517 | 0.190 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2024 | 2204 | 0.190 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2021 | 77 | 0.190 |
Why?
|
Estradiol | 2 | 2017 | 1935 | 0.190 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2021 | 67 | 0.190 |
Why?
|
Neoadjuvant Therapy | 4 | 2020 | 2821 | 0.190 |
Why?
|
Government Agencies | 1 | 2021 | 160 | 0.180 |
Why?
|
Lamins | 1 | 2020 | 37 | 0.180 |
Why?
|
Acetates | 1 | 2022 | 321 | 0.180 |
Why?
|
Proto-Oncogene Proteins | 5 | 2018 | 4509 | 0.180 |
Why?
|
Coenzyme A Ligases | 1 | 2020 | 45 | 0.180 |
Why?
|
Follow-Up Studies | 20 | 2021 | 39078 | 0.180 |
Why?
|
Glucocorticoids | 2 | 2021 | 2163 | 0.180 |
Why?
|
Enzyme Activation | 6 | 2017 | 3592 | 0.180 |
Why?
|
Ki-67 Antigen | 2 | 2016 | 629 | 0.180 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2004 | 677 | 0.170 |
Why?
|
Glioblastoma | 3 | 2024 | 3481 | 0.170 |
Why?
|
Intention to Treat Analysis | 4 | 2015 | 414 | 0.170 |
Why?
|
Fibroblast Growth Factor 1 | 1 | 2019 | 56 | 0.170 |
Why?
|
High-Throughput Screening Assays | 4 | 2019 | 934 | 0.170 |
Why?
|
Oxazoles | 1 | 2021 | 199 | 0.170 |
Why?
|
Phenotype | 10 | 2018 | 16585 | 0.170 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2018 | 940 | 0.160 |
Why?
|
Mice, Inbred NOD | 6 | 2021 | 1824 | 0.160 |
Why?
|
Immune Evasion | 1 | 2023 | 363 | 0.160 |
Why?
|
Lamin Type A | 1 | 2020 | 187 | 0.160 |
Why?
|
Drug Synergism | 3 | 2019 | 1755 | 0.160 |
Why?
|
B-Lymphocytes | 3 | 2021 | 4748 | 0.160 |
Why?
|
Biological Availability | 2 | 2018 | 390 | 0.160 |
Why?
|
Sirolimus | 4 | 2015 | 1533 | 0.160 |
Why?
|
Neural Crest | 1 | 2021 | 279 | 0.160 |
Why?
|
Spheroids, Cellular | 6 | 2023 | 329 | 0.160 |
Why?
|
Antacids | 1 | 2019 | 94 | 0.160 |
Why?
|
Academies and Institutes | 1 | 2021 | 318 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 2 | 2022 | 726 | 0.160 |
Why?
|
Retinoid X Receptor gamma | 1 | 2018 | 3 | 0.160 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 2 | 2016 | 83 | 0.160 |
Why?
|
POU Domain Factors | 1 | 2018 | 47 | 0.160 |
Why?
|
Albumins | 2 | 2020 | 575 | 0.160 |
Why?
|
Mucous Membrane | 4 | 2019 | 657 | 0.160 |
Why?
|
Adaptation, Biological | 1 | 2019 | 147 | 0.160 |
Why?
|
T-Lymphocytes | 5 | 2018 | 10188 | 0.160 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2019 | 1889 | 0.160 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 425 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 544 | 0.150 |
Why?
|
Models, Biological | 8 | 2019 | 9462 | 0.150 |
Why?
|
Lymphatic Metastasis | 5 | 2017 | 2912 | 0.150 |
Why?
|
Paired Box Transcription Factors | 2 | 2016 | 206 | 0.150 |
Why?
|
Cytokines | 5 | 2023 | 7377 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2509 | 0.150 |
Why?
|
Nerve Tissue Proteins | 2 | 2021 | 4413 | 0.150 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1008 | 0.150 |
Why?
|
Exosomes | 1 | 2022 | 424 | 0.150 |
Why?
|
Phosphorylation | 11 | 2022 | 8311 | 0.150 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2020 | 1725 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 214 | 0.150 |
Why?
|
Yttrium Radioisotopes | 1 | 2018 | 107 | 0.150 |
Why?
|
Melanoma, Amelanotic | 1 | 2017 | 19 | 0.140 |
Why?
|
RNA Stability | 1 | 2019 | 331 | 0.140 |
Why?
|
Pulmonary Fibrosis | 1 | 2001 | 505 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2015 | 570 | 0.140 |
Why?
|
Doxorubicin | 1 | 2004 | 2215 | 0.140 |
Why?
|
p21-Activated Kinases | 1 | 2017 | 128 | 0.140 |
Why?
|
Glioma | 2 | 2022 | 3434 | 0.140 |
Why?
|
STAT3 Transcription Factor | 2 | 2018 | 870 | 0.140 |
Why?
|
Subretinal Fluid | 1 | 2016 | 24 | 0.140 |
Why?
|
Pancreatic Neoplasms | 3 | 2020 | 5359 | 0.140 |
Why?
|
Oxidoreductases | 2 | 2016 | 412 | 0.140 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2016 | 27 | 0.130 |
Why?
|
Gene Fusion | 1 | 2019 | 354 | 0.130 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 694 | 0.130 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2015 | 17 | 0.130 |
Why?
|
Retinoblastoma Protein | 4 | 2014 | 671 | 0.130 |
Why?
|
Liver Neoplasms | 4 | 2018 | 4319 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2020 | 1766 | 0.130 |
Why?
|
Antigens, Nuclear | 1 | 2016 | 184 | 0.130 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2017 | 617 | 0.130 |
Why?
|
Antigen Presentation | 2 | 2019 | 1254 | 0.130 |
Why?
|
Calcium Channels | 1 | 2019 | 620 | 0.130 |
Why?
|
Hypopigmentation | 1 | 2015 | 43 | 0.130 |
Why?
|
Granzymes | 1 | 2017 | 277 | 0.130 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2016 | 112 | 0.130 |
Why?
|
Keratoacanthoma | 2 | 2012 | 33 | 0.130 |
Why?
|
Nuclear Proteins | 3 | 2020 | 5794 | 0.120 |
Why?
|
Guanidines | 1 | 2016 | 192 | 0.120 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2015 | 178 | 0.120 |
Why?
|
Risk Assessment | 11 | 2021 | 23953 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2018 | 390 | 0.120 |
Why?
|
Janus Kinase 1 | 1 | 2015 | 107 | 0.120 |
Why?
|
Dogs | 2 | 2018 | 3839 | 0.120 |
Why?
|
NAD | 2 | 2016 | 614 | 0.120 |
Why?
|
Compassionate Use Trials | 1 | 2014 | 50 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2013 | 184 | 0.120 |
Why?
|
Gene Knockdown Techniques | 6 | 2015 | 1610 | 0.120 |
Why?
|
Fibronectins | 2 | 2015 | 723 | 0.120 |
Why?
|
Drug Industry | 1 | 2021 | 788 | 0.120 |
Why?
|
Cisplatin | 4 | 2017 | 1647 | 0.120 |
Why?
|
Endoplasmic Reticulum | 2 | 2018 | 1133 | 0.120 |
Why?
|
Computational Biology | 2 | 2019 | 3510 | 0.120 |
Why?
|
Fibroblasts | 3 | 2020 | 4106 | 0.120 |
Why?
|
Adenomatous Polyps | 1 | 2015 | 108 | 0.120 |
Why?
|
Amino Acid Substitution | 6 | 2015 | 1737 | 0.120 |
Why?
|
Hepatocyte Growth Factor | 2 | 2014 | 270 | 0.120 |
Why?
|
Body Mass Index | 2 | 2018 | 12932 | 0.120 |
Why?
|
Lactams, Macrocyclic | 1 | 2016 | 318 | 0.120 |
Why?
|
Drug Tolerance | 1 | 2016 | 367 | 0.120 |
Why?
|
Quinolines | 3 | 2017 | 764 | 0.120 |
Why?
|
Sunlight | 2 | 2013 | 337 | 0.120 |
Why?
|
Fatigue | 2 | 2019 | 1550 | 0.120 |
Why?
|
Patient Rights | 1 | 2014 | 125 | 0.110 |
Why?
|
Salvage Therapy | 3 | 2020 | 1264 | 0.110 |
Why?
|
Autoimmunity | 1 | 2022 | 1355 | 0.110 |
Why?
|
Infection Control | 1 | 2021 | 985 | 0.110 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2014 | 103 | 0.110 |
Why?
|
Retrospective Studies | 21 | 2022 | 80430 | 0.110 |
Why?
|
Cell Cycle Proteins | 5 | 2022 | 3446 | 0.110 |
Why?
|
Valine | 5 | 2016 | 408 | 0.110 |
Why?
|
Genome | 2 | 2022 | 1739 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 643 | 0.110 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2013 | 43 | 0.110 |
Why?
|
Tumor Burden | 5 | 2021 | 1887 | 0.110 |
Why?
|
Thiazoles | 1 | 2021 | 1513 | 0.110 |
Why?
|
Promoter Regions, Genetic | 4 | 2018 | 5778 | 0.110 |
Why?
|
RNA, Small Interfering | 7 | 2016 | 3428 | 0.110 |
Why?
|
Age Factors | 5 | 2019 | 18379 | 0.110 |
Why?
|
Anilides | 2 | 2014 | 409 | 0.110 |
Why?
|
Oxidation-Reduction | 1 | 2019 | 2227 | 0.110 |
Why?
|
Nevus, Pigmented | 1 | 2015 | 221 | 0.110 |
Why?
|
Pyridinium Compounds | 1 | 2013 | 81 | 0.110 |
Why?
|
Melanoma-Specific Antigens | 1 | 2013 | 74 | 0.110 |
Why?
|
Telomerase | 1 | 2018 | 745 | 0.100 |
Why?
|
Autophagy | 4 | 2018 | 1319 | 0.100 |
Why?
|
Risk Factors | 15 | 2021 | 74055 | 0.100 |
Why?
|
Prospective Studies | 14 | 2022 | 54339 | 0.100 |
Why?
|
Nelfinavir | 2 | 2016 | 68 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1337 | 0.100 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
Mice, Inbred C57BL | 10 | 2021 | 22121 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 5 | 2019 | 17854 | 0.100 |
Why?
|
Karyopherins | 1 | 2013 | 132 | 0.100 |
Why?
|
Immunohistochemistry | 9 | 2017 | 11070 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2001 | 1874 | 0.100 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3541 | 0.100 |
Why?
|
Carcinoma, Ductal | 1 | 2012 | 97 | 0.100 |
Why?
|
Drug Approval | 2 | 2017 | 811 | 0.100 |
Why?
|
Pruritus | 1 | 2015 | 378 | 0.100 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 727 | 0.100 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 367 | 0.100 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 471 | 0.100 |
Why?
|
Butadienes | 5 | 2011 | 107 | 0.100 |
Why?
|
Lymph Nodes | 2 | 2014 | 3469 | 0.100 |
Why?
|
Skin Ulcer | 1 | 2013 | 129 | 0.100 |
Why?
|
Phosphorylcholine | 1 | 2012 | 153 | 0.100 |
Why?
|
Critical Pathways | 1 | 2015 | 474 | 0.100 |
Why?
|
Mice, Knockout | 8 | 2019 | 14397 | 0.100 |
Why?
|
Down-Regulation | 5 | 2022 | 2911 | 0.100 |
Why?
|
Ventricular Function, Left | 2 | 2022 | 3876 | 0.090 |
Why?
|
Fatty Acids | 1 | 2019 | 1805 | 0.090 |
Why?
|
Neurofibromin 1 | 3 | 2021 | 190 | 0.090 |
Why?
|
Adolescent | 12 | 2022 | 88196 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2423 | 0.090 |
Why?
|
Gene Expression Profiling | 7 | 2019 | 9410 | 0.090 |
Why?
|
Dextromethorphan | 1 | 2011 | 37 | 0.090 |
Why?
|
HEK293 Cells | 5 | 2020 | 4277 | 0.090 |
Why?
|
Mitotic Index | 1 | 2011 | 161 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2013 | 656 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2018 | 2646 | 0.090 |
Why?
|
MicroRNAs | 2 | 2017 | 3796 | 0.090 |
Why?
|
Reimbursement Mechanisms | 1 | 2016 | 664 | 0.090 |
Why?
|
Mitosis | 2 | 2013 | 1186 | 0.090 |
Why?
|
Farnesyltranstransferase | 1 | 2010 | 71 | 0.090 |
Why?
|
Mitochondria | 4 | 2022 | 3624 | 0.090 |
Why?
|
Stroke Volume | 2 | 2022 | 5487 | 0.090 |
Why?
|
Wnt Proteins | 1 | 2014 | 718 | 0.090 |
Why?
|
Interleukin-2 | 5 | 2019 | 1891 | 0.090 |
Why?
|
Disease Models, Animal | 11 | 2019 | 18216 | 0.090 |
Why?
|
Omeprazole | 1 | 2011 | 105 | 0.090 |
Why?
|
Craniotomy | 1 | 2015 | 741 | 0.090 |
Why?
|
Colonic Polyps | 1 | 2015 | 552 | 0.090 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1347 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2017 | 2297 | 0.090 |
Why?
|
Heparin | 1 | 2017 | 1633 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1745 | 0.090 |
Why?
|
Neoplasm Transplantation | 4 | 2017 | 2014 | 0.090 |
Why?
|
Transcription Factors | 8 | 2018 | 12121 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 7 | 2018 | 36362 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2017 | 1929 | 0.080 |
Why?
|
Neoplasm Invasiveness | 6 | 2014 | 3587 | 0.080 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 929 | 0.080 |
Why?
|
DNA Repair | 1 | 2019 | 2044 | 0.080 |
Why?
|
Bayes Theorem | 1 | 2017 | 2326 | 0.080 |
Why?
|
Microsomes | 1 | 2009 | 251 | 0.080 |
Why?
|
Spectrum Analysis | 1 | 2011 | 451 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 119 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 768 | 0.080 |
Why?
|
Antigens, Neoplasm | 5 | 2021 | 1994 | 0.080 |
Why?
|
Midazolam | 1 | 2011 | 266 | 0.080 |
Why?
|
Radiosurgery | 1 | 2019 | 1341 | 0.080 |
Why?
|
Cell Growth Processes | 4 | 2012 | 384 | 0.080 |
Why?
|
Up-Regulation | 5 | 2020 | 4116 | 0.080 |
Why?
|
Transfection | 4 | 2020 | 5776 | 0.080 |
Why?
|
Multiprotein Complexes | 2 | 2013 | 1119 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 367 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2413 | 0.080 |
Why?
|
Precancerous Conditions | 1 | 2016 | 978 | 0.080 |
Why?
|
Morpholines | 3 | 2008 | 580 | 0.080 |
Why?
|
Salivary Gland Neoplasms | 1 | 2012 | 304 | 0.080 |
Why?
|
Hypertension | 2 | 2006 | 8527 | 0.080 |
Why?
|
Smoking | 1 | 2005 | 9046 | 0.080 |
Why?
|
Vomiting | 3 | 2020 | 652 | 0.080 |
Why?
|
Embolization, Therapeutic | 1 | 2018 | 1418 | 0.080 |
Why?
|
Inhibitory Concentration 50 | 1 | 2009 | 465 | 0.080 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 856 | 0.080 |
Why?
|
Drug Interactions | 2 | 2011 | 1415 | 0.080 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 15257 | 0.080 |
Why?
|
Mutation, Missense | 5 | 2020 | 2571 | 0.080 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1974 | 0.070 |
Why?
|
Cell Survival | 5 | 2017 | 5790 | 0.070 |
Why?
|
Gene Targeting | 1 | 2011 | 838 | 0.070 |
Why?
|
Kinetics | 1 | 2015 | 6377 | 0.070 |
Why?
|
Radiology | 1 | 2021 | 2112 | 0.070 |
Why?
|
RNA, Messenger | 5 | 2024 | 12785 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2019 | 4355 | 0.070 |
Why?
|
Organoids | 2 | 2024 | 741 | 0.070 |
Why?
|
Stress, Physiological | 1 | 2014 | 1400 | 0.070 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6475 | 0.070 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 305 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2013 | 2008 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2247 | 0.070 |
Why?
|
Nitriles | 5 | 2011 | 969 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 2017 | 0.070 |
Why?
|
Alternative Splicing | 1 | 2011 | 1091 | 0.070 |
Why?
|
Protein Multimerization | 1 | 2011 | 982 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2757 | 0.070 |
Why?
|
Endothelial Cells | 3 | 2016 | 3541 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 557 | 0.070 |
Why?
|
Proteomics | 5 | 2021 | 3818 | 0.070 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 192 | 0.070 |
Why?
|
Calcium | 1 | 2019 | 5726 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7380 | 0.070 |
Why?
|
Genotype | 6 | 2019 | 12976 | 0.060 |
Why?
|
Teratoma | 1 | 2009 | 402 | 0.060 |
Why?
|
Transforming Growth Factor beta | 3 | 2020 | 1959 | 0.060 |
Why?
|
Plasma Cells | 1 | 2009 | 599 | 0.060 |
Why?
|
Glutamic Acid | 4 | 2016 | 1175 | 0.060 |
Why?
|
Sequence Analysis, RNA | 3 | 2022 | 2018 | 0.060 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2005 | 78 | 0.060 |
Why?
|
Stromal Cells | 3 | 2017 | 1330 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2012 | 823 | 0.060 |
Why?
|
Blotting, Western | 4 | 2015 | 5031 | 0.060 |
Why?
|
Polyglutamic Acid | 1 | 2005 | 47 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1953 | 0.060 |
Why?
|
Base Sequence | 4 | 2019 | 12449 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 1428 | 0.060 |
Why?
|
Drug Monitoring | 3 | 2017 | 961 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2017 | 441 | 0.060 |
Why?
|
Activating Transcription Factor 4 | 2 | 2017 | 84 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2007 | 409 | 0.060 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 617 | 0.060 |
Why?
|
Proteins | 2 | 2018 | 6033 | 0.060 |
Why?
|
DNA Methylation | 2 | 2016 | 4383 | 0.060 |
Why?
|
RNA | 3 | 2022 | 2721 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 696 | 0.060 |
Why?
|
Sample Size | 1 | 2008 | 839 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 2 | 2014 | 2803 | 0.060 |
Why?
|
Drug Resistance | 1 | 2010 | 1597 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1703 | 0.060 |
Why?
|
Recombinant Proteins | 2 | 2016 | 6525 | 0.060 |
Why?
|
Glucose | 1 | 2016 | 4342 | 0.060 |
Why?
|
Kidney | 1 | 2019 | 7046 | 0.060 |
Why?
|
Skin Diseases | 1 | 2012 | 1090 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2006 | 584 | 0.060 |
Why?
|
Glycolysis | 2 | 2019 | 832 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 491 | 0.060 |
Why?
|
Rats | 2 | 2018 | 23712 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2019 | 1870 | 0.060 |
Why?
|
SOXE Transcription Factors | 1 | 2023 | 73 | 0.050 |
Why?
|
HT29 Cells | 2 | 2015 | 192 | 0.050 |
Why?
|
Cost of Illness | 1 | 2013 | 1931 | 0.050 |
Why?
|
Culture Media, Conditioned | 2 | 2016 | 522 | 0.050 |
Why?
|
Organometallic Compounds | 1 | 2007 | 649 | 0.050 |
Why?
|
Tomography, Optical Coherence | 1 | 2016 | 2907 | 0.050 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 107 | 0.050 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2852 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2020 | 1340 | 0.050 |
Why?
|
Protein Binding | 5 | 2015 | 9340 | 0.050 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 27 | 0.050 |
Why?
|
Endoribonucleases | 1 | 2024 | 228 | 0.050 |
Why?
|
Massachusetts | 3 | 2021 | 8826 | 0.050 |
Why?
|
Immunoprecipitation | 2 | 2015 | 877 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Succinates | 1 | 2022 | 81 | 0.050 |
Why?
|
Gene Expression | 4 | 2019 | 7582 | 0.050 |
Why?
|
Research | 1 | 2011 | 1977 | 0.050 |
Why?
|
Neoplasms, Experimental | 2 | 2017 | 1228 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 8 | 2017 | 20551 | 0.050 |
Why?
|
Receptors, Death Domain | 1 | 2022 | 31 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 188 | 0.050 |
Why?
|
Thrombocytopenia | 3 | 2005 | 1174 | 0.050 |
Why?
|
Doxycycline | 2 | 2015 | 344 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2015 | 3782 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 249 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1607 | 0.050 |
Why?
|
beta Catenin | 2 | 2017 | 1040 | 0.050 |
Why?
|
Autoantibodies | 2 | 2022 | 2123 | 0.050 |
Why?
|
Genes, bcl-2 | 1 | 2001 | 119 | 0.050 |
Why?
|
Protein Kinase C-alpha | 1 | 2001 | 113 | 0.050 |
Why?
|
Taxoids | 1 | 2005 | 666 | 0.050 |
Why?
|
Benchmarking | 1 | 2008 | 1045 | 0.050 |
Why?
|
Inflammation | 2 | 2020 | 10746 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2004 | 11095 | 0.050 |
Why?
|
Nucleosides | 1 | 2021 | 131 | 0.050 |
Why?
|
Genetic Heterogeneity | 1 | 2024 | 733 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2017 | 5865 | 0.050 |
Why?
|
Soft Tissue Neoplasms | 1 | 2009 | 1154 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2004 | 582 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3535 | 0.050 |
Why?
|
Interdisciplinary Studies | 1 | 2021 | 86 | 0.050 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2020 | 60 | 0.040 |
Why?
|
Osteolysis | 1 | 2002 | 275 | 0.040 |
Why?
|
Cohort Studies | 6 | 2024 | 41366 | 0.040 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2020 | 119 | 0.040 |
Why?
|
Placebos | 2 | 2019 | 1661 | 0.040 |
Why?
|
Liposomes | 1 | 2004 | 781 | 0.040 |
Why?
|
Mastocytosis | 1 | 2002 | 149 | 0.040 |
Why?
|
Point Mutation | 2 | 2017 | 1595 | 0.040 |
Why?
|
Pilot Projects | 2 | 2017 | 8611 | 0.040 |
Why?
|
Forecasting | 1 | 2009 | 2925 | 0.040 |
Why?
|
Tristetraprolin | 1 | 2019 | 38 | 0.040 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2021 | 361 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 876 | 0.040 |
Why?
|
HIV Protease Inhibitors | 2 | 2016 | 432 | 0.040 |
Why?
|
Lymphocyte Count | 2 | 2014 | 778 | 0.040 |
Why?
|
Italy | 2 | 2012 | 840 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 2015 | 1626 | 0.040 |
Why?
|
Microfluidic Analytical Techniques | 2 | 2017 | 803 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2014 | 732 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2014 | 2568 | 0.040 |
Why?
|
Mutant Proteins | 2 | 2011 | 491 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2021 | 468 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2018 | 6206 | 0.040 |
Why?
|
Heparitin Sulfate | 1 | 2020 | 223 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2005 | 710 | 0.040 |
Why?
|
Ligands | 2 | 2017 | 3270 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2013 | 2891 | 0.040 |
Why?
|
Dermis | 1 | 2020 | 202 | 0.040 |
Why?
|
Protein Isoforms | 2 | 2015 | 1697 | 0.040 |
Why?
|
Autocrine Communication | 1 | 2019 | 169 | 0.040 |
Why?
|
Wound Healing | 1 | 2010 | 2799 | 0.040 |
Why?
|
Sarcoma | 1 | 2009 | 1791 | 0.040 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2018 | 72 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 1 | 1998 | 106 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2019 | 316 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 12429 | 0.040 |
Why?
|
PPAR alpha | 1 | 2019 | 175 | 0.040 |
Why?
|
Mycoplasma hyorhinis | 1 | 2017 | 8 | 0.040 |
Why?
|
Gammaproteobacteria | 1 | 2017 | 28 | 0.040 |
Why?
|
Cell Culture Techniques | 2 | 2017 | 1667 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 2018 | 384 | 0.040 |
Why?
|
Algorithms | 2 | 2015 | 14002 | 0.040 |
Why?
|
Sulfones | 1 | 2020 | 447 | 0.040 |
Why?
|
Adaptor Protein Complex sigma Subunits | 1 | 2017 | 10 | 0.040 |
Why?
|
Infusions, Intravenous | 3 | 2010 | 2217 | 0.040 |
Why?
|
Viremia | 1 | 2020 | 707 | 0.040 |
Why?
|
Receptors, Interleukin-8B | 1 | 2017 | 57 | 0.040 |
Why?
|
NF-kappa B | 2 | 2017 | 2485 | 0.040 |
Why?
|
Caspase 9 | 1 | 2017 | 185 | 0.040 |
Why?
|
Chromones | 2 | 2008 | 148 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2019 | 1379 | 0.040 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2017 | 71 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2014 | 5421 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2021 | 1571 | 0.040 |
Why?
|
Chemokine CXCL1 | 1 | 2017 | 101 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2019 | 234 | 0.030 |
Why?
|
Aging | 1 | 2016 | 8689 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2001 | 1202 | 0.030 |
Why?
|
Dual Specificity Phosphatase 6 | 1 | 2016 | 13 | 0.030 |
Why?
|
Treatment Failure | 2 | 2018 | 2642 | 0.030 |
Why?
|
Acetanilides | 1 | 2018 | 169 | 0.030 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2019 | 353 | 0.030 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 329 | 0.030 |
Why?
|
Arginine | 1 | 2020 | 933 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
RNA Interference | 2 | 2016 | 2832 | 0.030 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2020 | 599 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12054 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.030 |
Why?
|
Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
Transcriptional Activation | 2 | 2015 | 1753 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2017 | 411 | 0.030 |
Why?
|
Receptors, Interleukin-1 | 1 | 2017 | 262 | 0.030 |
Why?
|
Keratinocytes | 1 | 2020 | 790 | 0.030 |
Why?
|
Genes, p16 | 1 | 2016 | 159 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2022 | 1314 | 0.030 |
Why?
|
Wnt1 Protein | 1 | 2016 | 120 | 0.030 |
Why?
|
Apyrase | 1 | 2018 | 373 | 0.030 |
Why?
|
DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2016 | 72 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2017 | 18955 | 0.030 |
Why?
|
Nurses | 1 | 2005 | 2471 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 851 | 0.030 |
Why?
|
Cellulitis | 1 | 2017 | 209 | 0.030 |
Why?
|
G1 Phase | 2 | 2007 | 403 | 0.030 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2017 | 783 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 12918 | 0.030 |
Why?
|
Exons | 2 | 2011 | 2392 | 0.030 |
Why?
|
Drugs, Investigational | 1 | 2017 | 212 | 0.030 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 285 | 0.030 |
Why?
|
Integrin alpha5beta1 | 1 | 2015 | 37 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2017 | 591 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 659 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2016 | 285 | 0.030 |
Why?
|
Cell Movement | 2 | 2019 | 5198 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2014 | 115 | 0.030 |
Why?
|
Data Collection | 1 | 2024 | 3321 | 0.030 |
Why?
|
Caspase 3 | 1 | 2017 | 729 | 0.030 |
Why?
|
Germ Cells | 1 | 2019 | 634 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2016 | 222 | 0.030 |
Why?
|
Genes, APC | 1 | 2015 | 144 | 0.030 |
Why?
|
Neurofibromin 2 | 1 | 2016 | 270 | 0.030 |
Why?
|
Therapies, Investigational | 1 | 2015 | 111 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9533 | 0.030 |
Why?
|
Fundus Oculi | 1 | 2016 | 548 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2265 | 0.030 |
Why?
|
Heat-Shock Proteins | 1 | 2018 | 795 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2008 | 2331 | 0.030 |
Why?
|
Brain | 2 | 2019 | 27060 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2016 | 225 | 0.030 |
Why?
|
Benzocycloheptenes | 1 | 2014 | 9 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 2015 | 321 | 0.030 |
Why?
|
Scleroderma, Systemic | 1 | 1998 | 344 | 0.030 |
Why?
|
Antigens, CD | 2 | 2018 | 4000 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2504 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 14661 | 0.030 |
Why?
|
Clobetasol | 1 | 2014 | 33 | 0.030 |
Why?
|
Interleukins | 1 | 2019 | 782 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2001 | 1373 | 0.030 |
Why?
|
Glutarates | 1 | 2015 | 243 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2017 | 696 | 0.030 |
Why?
|
Immunocompetence | 1 | 2014 | 138 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 1218 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 359 | 0.030 |
Why?
|
Gastroscopy | 1 | 2015 | 210 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.030 |
Why?
|
Anemia | 1 | 2003 | 1508 | 0.030 |
Why?
|
Ribosomal Protein S6 | 1 | 2013 | 71 | 0.030 |
Why?
|
Phylogeny | 1 | 2021 | 2806 | 0.030 |
Why?
|
CREB-Binding Protein | 1 | 2013 | 148 | 0.030 |
Why?
|
rab GTP-Binding Proteins | 1 | 2015 | 250 | 0.030 |
Why?
|
Indolizines | 1 | 2013 | 30 | 0.030 |
Why?
|
Interleukin-1 | 1 | 2017 | 1250 | 0.030 |
Why?
|
Cyclic N-Oxides | 1 | 2013 | 72 | 0.030 |
Why?
|
beta-Cyclodextrins | 1 | 2013 | 70 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20078 | 0.030 |
Why?
|
Protein Transport | 1 | 2018 | 1965 | 0.030 |
Why?
|
Molecular Weight | 1 | 2015 | 2188 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 281 | 0.030 |
Why?
|
Mohs Surgery | 1 | 2015 | 222 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1704 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2014 | 473 | 0.030 |
Why?
|
Philadelphia | 1 | 2013 | 266 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.030 |
Why?
|
Photosensitivity Disorders | 1 | 2012 | 80 | 0.030 |
Why?
|
Warts | 1 | 2012 | 66 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2015 | 597 | 0.030 |
Why?
|
Receptors, Interleukin-2 | 1 | 1993 | 562 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2016 | 5491 | 0.020 |
Why?
|
RNA, Viral | 1 | 2020 | 2846 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2012 | 361 | 0.020 |
Why?
|
Pandemics | 2 | 2023 | 8623 | 0.020 |
Why?
|
Immunoblotting | 1 | 2015 | 1647 | 0.020 |
Why?
|
Oncogenes | 1 | 2017 | 1223 | 0.020 |
Why?
|
Keratosis, Actinic | 1 | 2012 | 72 | 0.020 |
Why?
|
Telomere | 1 | 2018 | 931 | 0.020 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7597 | 0.020 |
Why?
|
Osteoporosis | 1 | 2001 | 1603 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 712 | 0.020 |
Why?
|
Device Approval | 1 | 2013 | 163 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1050 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2020 | 1899 | 0.020 |
Why?
|
Sex Factors | 1 | 2005 | 10538 | 0.020 |
Why?
|
Transgenes | 1 | 2015 | 1009 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 983 | 0.020 |
Why?
|
Viral Load | 1 | 2020 | 3329 | 0.020 |
Why?
|
Half-Life | 1 | 2012 | 652 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2017 | 997 | 0.020 |
Why?
|
Clone Cells | 1 | 2014 | 1660 | 0.020 |
Why?
|
Antibodies | 1 | 2019 | 2421 | 0.020 |
Why?
|
Colonic Neoplasms | 2 | 2017 | 2529 | 0.020 |
Why?
|
Aminolevulinic Acid | 1 | 2012 | 144 | 0.020 |
Why?
|
Protein Interaction Mapping | 1 | 2014 | 616 | 0.020 |
Why?
|
Fluorescein Angiography | 1 | 2016 | 1051 | 0.020 |
Why?
|
Chick Embryo | 1 | 2013 | 982 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2016 | 1125 | 0.020 |
Why?
|
Transcription Factor CHOP | 1 | 2010 | 68 | 0.020 |
Why?
|
Program Development | 1 | 2017 | 1297 | 0.020 |
Why?
|
gp100 Melanoma Antigen | 1 | 2010 | 38 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2020 | 3209 | 0.020 |
Why?
|
Diphenylamine | 1 | 2010 | 49 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2002 | 1890 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2010 | 65 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2014 | 353 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 1640 | 0.020 |
Why?
|
Cell Death | 1 | 2015 | 1664 | 0.020 |
Why?
|
Neuroblastoma | 1 | 2018 | 1250 | 0.020 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2010 | 105 | 0.020 |
Why?
|
Mitochondrial Proteins | 1 | 2016 | 979 | 0.020 |
Why?
|
Intestines | 1 | 2019 | 1909 | 0.020 |
Why?
|
Cell Line | 2 | 2017 | 15598 | 0.020 |
Why?
|
Drug Therapy | 1 | 2013 | 503 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3418 | 0.020 |
Why?
|
Cyclic AMP | 1 | 2013 | 1461 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2011 | 285 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 1975 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1504 | 0.020 |
Why?
|
Allosteric Regulation | 1 | 2010 | 426 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3155 | 0.020 |
Why?
|
Headache | 1 | 2017 | 1252 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2017 | 1891 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 2014 | 1003 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2006 | 4879 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2711 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3822 | 0.020 |
Why?
|
Cell Communication | 1 | 2016 | 1652 | 0.020 |
Why?
|
Immunoconjugates | 1 | 2016 | 953 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2015 | 1301 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 2468 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2010 | 901 | 0.020 |
Why?
|
Cell Separation | 1 | 2014 | 1720 | 0.020 |
Why?
|
Australia | 1 | 2012 | 1245 | 0.020 |
Why?
|
Lung Diseases | 1 | 1998 | 1909 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15820 | 0.020 |
Why?
|
Germany | 1 | 2010 | 873 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2016 | 2137 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2009 | 550 | 0.020 |
Why?
|
Universities | 1 | 2013 | 993 | 0.020 |
Why?
|
Bacteria | 1 | 2019 | 2217 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2189 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 590 | 0.020 |
Why?
|
Nevus | 1 | 2009 | 205 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9326 | 0.020 |
Why?
|
Gene Library | 1 | 2010 | 1059 | 0.020 |
Why?
|
Gadolinium | 1 | 2013 | 960 | 0.020 |
Why?
|
Protein Structure, Tertiary | 2 | 2011 | 3792 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2014 | 1273 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1841 | 0.020 |
Why?
|
Gene Silencing | 1 | 2014 | 1509 | 0.020 |
Why?
|
Photosensitizing Agents | 1 | 2012 | 623 | 0.020 |
Why?
|
Metformin | 1 | 2015 | 905 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2010 | 15627 | 0.020 |
Why?
|
G2 Phase | 1 | 2007 | 136 | 0.020 |
Why?
|
Ruthenium | 1 | 2007 | 18 | 0.020 |
Why?
|
Open Reading Frames | 1 | 2010 | 815 | 0.020 |
Why?
|
Colonoscopy | 1 | 2015 | 1392 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2016 | 9598 | 0.020 |
Why?
|
cdc25 Phosphatases | 1 | 2007 | 60 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1183 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4558 | 0.020 |
Why?
|
Databases, Factual | 2 | 2013 | 7948 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 319 | 0.020 |
Why?
|
Visual Acuity | 1 | 2016 | 2662 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2007 | 401 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2011 | 1494 | 0.020 |
Why?
|
Gene Dosage | 1 | 2011 | 1218 | 0.020 |
Why?
|
Cell Membrane | 1 | 2016 | 3685 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2010 | 1792 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 825 | 0.020 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 58 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2927 | 0.020 |
Why?
|
Metabolomics | 1 | 2015 | 1653 | 0.020 |
Why?
|
Androstadienes | 1 | 2008 | 348 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5236 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 496 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2441 | 0.020 |
Why?
|
Child | 3 | 2023 | 80086 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2016 | 4287 | 0.020 |
Why?
|
Lower Extremity | 1 | 2014 | 1199 | 0.020 |
Why?
|
Zebrafish | 1 | 2017 | 3002 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 882 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4567 | 0.020 |
Why?
|
Leucovorin | 1 | 2007 | 642 | 0.020 |
Why?
|
Family Health | 1 | 1990 | 1257 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2016 | 2978 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3904 | 0.020 |
Why?
|
China | 1 | 2011 | 2339 | 0.020 |
Why?
|
Astrocytes | 1 | 2013 | 1345 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2016 | 3108 | 0.020 |
Why?
|
Demography | 1 | 2009 | 1648 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2016 | 2413 | 0.010 |
Why?
|
Flavonoids | 1 | 2008 | 444 | 0.010 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1024 | 0.010 |
Why?
|
Proteome | 1 | 2014 | 1861 | 0.010 |
Why?
|
Pain Measurement | 1 | 2015 | 3546 | 0.010 |
Why?
|
Cell Lineage | 1 | 2013 | 2539 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4549 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2875 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1135 | 0.010 |
Why?
|
Germ-Line Mutation | 1 | 2012 | 1850 | 0.010 |
Why?
|
Models, Molecular | 2 | 2010 | 5427 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 1780 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2015 | 3026 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14565 | 0.010 |
Why?
|
Stilbenes | 1 | 2005 | 155 | 0.010 |
Why?
|
Folic Acid Antagonists | 1 | 2004 | 75 | 0.010 |
Why?
|
Camptothecin | 1 | 2007 | 590 | 0.010 |
Why?
|
Immune System | 1 | 2009 | 794 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2001 | 5143 | 0.010 |
Why?
|
Medicine | 1 | 2011 | 941 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2014 | 2725 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 1463 | 0.010 |
Why?
|
Protein Subunits | 1 | 2006 | 942 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 3076 | 0.010 |
Why?
|
Fluorouracil | 1 | 2007 | 1637 | 0.010 |
Why?
|
Macrophages | 1 | 2017 | 5764 | 0.010 |
Why?
|
DNA Primers | 1 | 2006 | 2820 | 0.010 |
Why?
|
Health Status | 1 | 2015 | 4071 | 0.010 |
Why?
|
Bone Marrow Neoplasms | 1 | 2002 | 101 | 0.010 |
Why?
|
Safety | 1 | 2006 | 1150 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1990 | 2199 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8216 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2007 | 1183 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21322 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10698 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2009 | 4808 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2014 | 3072 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2008 | 17639 | 0.010 |
Why?
|
Regression Analysis | 1 | 2009 | 6340 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2009 | 4369 | 0.010 |
Why?
|
Cell Division | 1 | 2007 | 4461 | 0.010 |
Why?
|
Contrast Media | 1 | 2013 | 5310 | 0.010 |
Why?
|
Consensus | 1 | 2009 | 3115 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15867 | 0.010 |
Why?
|
Family | 1 | 1990 | 3189 | 0.010 |
Why?
|
Reference Values | 1 | 2006 | 4921 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2016 | 11526 | 0.010 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 1998 | 94 | 0.010 |
Why?
|
Chronic Disease | 1 | 2013 | 9309 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3777 | 0.010 |
Why?
|
Skin | 1 | 2011 | 4474 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22097 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2006 | 6086 | 0.010 |
Why?
|
Vital Capacity | 1 | 1998 | 970 | 0.010 |
Why?
|
RNA Polymerase II | 1 | 1998 | 539 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 1998 | 1812 | 0.010 |
Why?
|
HIV-1 | 1 | 1990 | 6859 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8967 | 0.010 |
Why?
|
Liver | 1 | 2007 | 7531 | 0.010 |
Why?
|
Heart Failure | 1 | 2015 | 11653 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1993 | 1693 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15476 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1993 | 3075 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11900 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1990 | 1596 | 0.000 |
Why?
|
Substance Abuse, Intravenous | 1 | 1990 | 530 | 0.000 |
Why?
|
Binding Sites | 1 | 1993 | 6042 | 0.000 |
Why?
|
HIV Seropositivity | 1 | 1990 | 960 | 0.000 |
Why?
|
HIV Antibodies | 1 | 1990 | 1302 | 0.000 |
Why?
|
DNA, Viral | 1 | 1990 | 2201 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1993 | 13445 | 0.000 |
Why?
|
Sexual Behavior | 1 | 1990 | 2178 | 0.000 |
Why?
|